News & Updates

Sotatercept, when added to background therapy, helps improve outcomes for children with pulmonary hypertension, as shown in a retrospective study.

Once-weekly TG103, a novel long-acting GLP-1*/Fc fusion protein, demonstrates noninferiority to dulaglutide in reducing HbA_1c in Chinese patients with type 2 diabetes (T2D) inadequately controlled on metformin, according to a phase III trial presented at EASD 2026.

Adolescents with moderate-to-severe chronic hand eczema report a considerable improvement in their quality of life following treatment with delgocitinib cream, according to data from the international phase III DELTA TEEN study.

A pharmacist monitoring programme has helped increase the use of sodium-glucose cotransporter 2 (SGLT2) inhibitors in patients with heart failure with an ejection fraction (HFEF) >40 percent, driven by improved documentation, according to a study.

Infusion of dexmedetomidine for 72 h and infusion rate at ≥1 mcg/kg/h appear to contribute to the development of fever in critically ill patients in a community teaching hospital, suggests a study.

In the treatment of moderate-to-severe plaque psoriasis, the investigational selective tyrosine kinase 2 (TYK2) inhibitor zasocitinib is associated with higher rates of skin clearance compared with the first-generation TYK2 inhibitor deucravacitinib, as shown in the head-to-head phase III LATITUDE Atlas trial.

Treatment with secukinumab results in improved clinical response at 12 months and is well tolerated in patients with hidradenitis suppurativa (HS), according to the ongoing SPECTRA study in France.

Topical ruxolitinib demonstrates significant clinical activity while having a favourable harms profile in the treatment of patients with cutaneous chronic graft-versus-host disease (cGVHD) in a phase II study.